ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

The ubiquitin-proteasome system has recently emerged as a major target for drug development in cancer therapy. The proteasome inhibitor bortezomib has clinical activity in multiple myeloma and mantle cell lymphoma. Here we report that Eeyarestatin I (EerI), a chemical inhibitor that blocks endoplasm...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wang, Qiuyan, Mora-Jensen, Helena, Weniger, Marc A., Perez-Galan, Patricia, Wolford, Chris, Hai, Tsonwin, Ron, David, Chen, Weiping, Trenkle, William, Wiestner, Adrian, Ye, Yihong
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2009
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2629785/
https://ncbi.nlm.nih.gov/pubmed/19164757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0807611106
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars